Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Composition",
"id" : "370512",
"meta" : {
"versionId" : "9",
"lastUpdated" : "2025-07-14T11:06:46.807Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 370512</b></p><a name=\"370512\"> </a><a name=\"hc370512\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 9; Last updated: 2025-07-14 11:06:46+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-report.html\">ParticipantFlowReport</a></p></div><p><b>Artifact Description</b>: </p><div><p>Example for EBMonFHIR IG</p>\n</div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/370512\">https://fevir.net/resources/Composition/370512</a></p><p><b>identifier</b>: FEvIR Object Identifier/370512, FEvIR Linking Identifier/NCT03640312-participant-flow-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowReport}\">Participant Flow Report</span></p><p><b>date</b>: 2025-07-14 11:06:46+0000</p><p><b>author</b>: Joanne Dehnbostel</p><p><b>title</b>: Participant Flow Report for QUARTET USA Trial</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cite As</p><p><b>target</b>: </p><div><p>Participant Flow Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370512. Revised 2025-07-14. Available at: https://fevir.net/resources/Composition/370512. Computable resource at: https://fevir.net/FLI/DocumentForComposition370512.</p>\n</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Derived From</p><p><b>target</b>: <a href=\"Composition-370502.html\">Participant Flow Report for NCT03640312</a></p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Group #ScreenedGroup</b></p><a name=\"370512/ScreenedGroup\"> </a><a name=\"hc370512/ScreenedGroup\"> </a><p><b>name</b>: Group Screened for Participation for QUARTET USA Trial</p><p><b>description</b>: </p><div><p>Potentially eligible patients screened for participation in the QUARTET USA Trial</p>\n</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><p><b>quantity</b>: 120</p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Group #FG000</b></p><a name=\"370512/FG000\"> </a><a name=\"hc370512/FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profiles: <a href=\"StructureDefinition-comparator-group.html\">ComparatorGroup</a>, <a href=\"StructureDefinition-exposure-group.html\">ExposureGroup</a>, <a href=\"StructureDefinition-study-group.html\">StudyGroup</a></p></div><p><b>name</b>: NCT03640312 Flow Group QUARTET LDQT</p><p><b>description</b>: </p><div><p>Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.</p>\n<p>QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</p>\n</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><p><b>quantity</b>: 32</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Research Study from which this is a flow group</span></td><td>NCT03640312</td><td>false</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Group #FG001</b></p><a name=\"370512/FG001\"> </a><a name=\"hc370512/FG001\"> </a><p><b>name</b>: NCT03640312 Flow Group Candesartan</p><p><b>description</b>: </p><div><p>Patients randomized to the comparison arm took a once daily 8mg candesartan.</p>\n<p>Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</p>\n</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><p><b>quantity</b>: 30</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Research Study from which this is a flow group</span></td><td>NCT03640312</td><td>false</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #ExcludedCount</b></p><a name=\"370512/ExcludedCount\"> </a><a name=\"hc370512/ExcludedCount\"> </a><p><b>title</b>: Excluded from QUARTET USA Trial</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Screened for Participation</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/ScreenedGroup\">Screened for Participation</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Excluded</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Excluded</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">count</span></td><td>58</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #ReasonsForExclusion</b></p><a name=\"370512/ReasonsForExclusion\"> </a><a name=\"hc370512/ReasonsForExclusion\"> </a><p><b>title</b>: Reasons for exclusion from QUARTET USA Trial</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Screened for Participation</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/ScreenedGroup\">Screened for Participation</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Reasons for exclusion from QUARTET USA Trial</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-372461.html\">Reasons for exclusion from QUARTET USA Trial</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">count</span></p><p><b>category</b>: <span title=\"Codes:\">Not meeting inclusion criteria</span></p><p><b>quantity</b>: 56</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">count</span></p><p><b>category</b>: <span title=\"Codes:\">Other reasons: "no-shows" for randomization</span></p><p><b>quantity</b>: 2</p></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-0-Overall-Study-group-FG000</b></p><a name=\"370512/NCT03640312-flow-milestone-0-Overall-Study-group-FG000\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-0-Overall-Study-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-0-Overall-Study-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG000\">QUARTET LDQT</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-0-Overall-Study-group-FG001</b></p><a name=\"370512/NCT03640312-flow-milestone-0-Overall-Study-group-FG001\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-0-Overall-Study-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-0-Overall-Study-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG001\">Candesartan</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>30</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-1-Overall-Study-group-FG000</b></p><a name=\"370512/NCT03640312-flow-milestone-1-Overall-Study-group-FG000\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-1-Overall-Study-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-1-Overall-Study-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG000\">QUARTET LDQT</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: 6 Week Follow Up at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-1-Overall-Study-group-FG001</b></p><a name=\"370512/NCT03640312-flow-milestone-1-Overall-Study-group-FG001\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-1-Overall-Study-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-1-Overall-Study-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG001\">Candesartan</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: 6 Week Follow Up at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>28</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-2-Overall-Study-group-FG000</b></p><a name=\"370512/NCT03640312-flow-milestone-2-Overall-Study-group-FG000\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-2-Overall-Study-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-2-Overall-Study-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG000\">QUARTET LDQT</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>29</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-2-Overall-Study-group-FG001</b></p><a name=\"370512/NCT03640312-flow-milestone-2-Overall-Study-group-FG001\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-2-Overall-Study-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-2-Overall-Study-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG001\">Candesartan</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>24</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-3-Overall-Study-group-FG000</b></p><a name=\"370512/NCT03640312-flow-milestone-3-Overall-Study-group-FG000\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-3-Overall-Study-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-3-Overall-Study-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG000\">QUARTET LDQT</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>3</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-milestone-3-Overall-Study-group-FG001</b></p><a name=\"370512/NCT03640312-flow-milestone-3-Overall-Study-group-FG001\"> </a><a name=\"hc370512/NCT03640312-flow-milestone-3-Overall-Study-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-milestone-3-Overall-Study-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG001\">Candesartan</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td>6</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-reason-Overall-Study-group-FG000</b></p><a name=\"370512/NCT03640312-flow-reason-Overall-Study-group-FG000\"> </a><a name=\"hc370512/NCT03640312-flow-reason-Overall-Study-group-FG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-reason-Overall-Study-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG000\">QUARTET LDQT</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Reasons for withdraw at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Category</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td><span title=\"Codes:\">Lost to Follow-up</span></td><td>3</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03640312-flow-reason-Overall-Study-group-FG001</b></p><a name=\"370512/NCT03640312-flow-reason-Overall-Study-group-FG001\"> </a><a name=\"hc370512/NCT03640312-flow-reason-Overall-Study-group-FG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-participant-flow-evidence.html\">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03640312-flow-reason-Overall-Study-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}\">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"#hc370512/FG001\">Candesartan</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Reasons for withdraw at Overall Study</p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>StatisticType</b></td><td><b>Category</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000047}\">Count</span></td><td><span title=\"Codes:\">Lost to Follow-up</span></td><td>6</td></tr></table></blockquote></div>"
},
"contained" : [
{
"resourceType" : "Group",
"id" : "ScreenedGroup",
"name" : "Group Screened for Participation for QUARTET USA Trial",
"description" : "Potentially eligible patients screened for participation in the QUARTET USA Trial",
"type" : "person",
"membership" : "enumerated",
"quantity" : 120
},
{
"resourceType" : "Group",
"id" : "FG000",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-group"🔗 ,
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"🔗 ,
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-group"
]
},
"name" : "NCT03640312 Flow Group QUARTET LDQT",
"description" : "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.",
"type" : "person",
"membership" : "enumerated",
"quantity" : 32,
"characteristic" : [
{
"code" : {
"text" : "Research Study from which this is a flow group"
},
"valueReference" : {
"display" : "NCT03640312"
},
"exclude" : false
}
]
},
{
"resourceType" : "Group",
"id" : "FG001",
"name" : "NCT03640312 Flow Group Candesartan",
"description" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.",
"type" : "person",
"membership" : "enumerated",
"quantity" : 30,
"characteristic" : [
{
"code" : {
"text" : "Research Study from which this is a flow group"
},
"valueReference" : {
"display" : "NCT03640312"
},
"exclude" : false
}
]
},
{
"resourceType" : "Evidence",
"id" : "ExcludedCount",
"title" : "Excluded from QUARTET USA Trial",
"status" : "active",
"variableDefinition" : [
{
"description" : "Screened for Participation",
"variableRole" : "population",
"observed" : {
"reference" : "#ScreenedGroup",
"type" : "Group",
"display" : "Screened for Participation"
}
},
{
"description" : "Excluded",
"variableRole" : "outcome",
"observed" : {
"type" : "EvidenceVariable",
"display" : "Excluded"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "count"
}
]
},
"quantity" : {
"value" : 58
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "ReasonsForExclusion",
"title" : "Reasons for exclusion from QUARTET USA Trial",
"status" : "active",
"variableDefinition" : [
{
"description" : "Screened for Participation",
"variableRole" : "population",
"observed" : {
"reference" : "#ScreenedGroup",
"type" : "Group",
"display" : "Screened for Participation"
}
},
{
"description" : "Reasons for exclusion from QUARTET USA Trial",
"variableRole" : "outcome",
"observed" : {
🔗 "reference" : "EvidenceVariable/372461",
"type" : "EvidenceVariable",
"display" : "Reasons for exclusion from QUARTET USA Trial"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "count"
}
]
},
"category" : {
"text" : "Not meeting inclusion criteria"
},
"quantity" : {
"value" : 56
}
},
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "count"
}
]
},
"category" : {
"text" : "Other reasons: \"no-shows\" for randomization"
},
"quantity" : {
"value" : 2
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-0-Overall-Study-group-FG000",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-0-Overall-Study-group-FG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG000",
"type" : "Group",
"display" : "QUARTET LDQT"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "STARTED at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 32
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-0-Overall-Study-group-FG001",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-0-Overall-Study-group-FG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG001",
"type" : "Group",
"display" : "Candesartan"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "STARTED at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 30
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-1-Overall-Study-group-FG000",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-1-Overall-Study-group-FG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG000",
"type" : "Group",
"display" : "QUARTET LDQT"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "6 Week Follow Up at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 32
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-1-Overall-Study-group-FG001",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-1-Overall-Study-group-FG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG001",
"type" : "Group",
"display" : "Candesartan"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "6 Week Follow Up at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 28
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-2-Overall-Study-group-FG000",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-2-Overall-Study-group-FG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG000",
"type" : "Group",
"display" : "QUARTET LDQT"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "COMPLETED at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 29
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-2-Overall-Study-group-FG001",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-2-Overall-Study-group-FG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG001",
"type" : "Group",
"display" : "Candesartan"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "COMPLETED at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 24
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-3-Overall-Study-group-FG000",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-3-Overall-Study-group-FG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG000",
"type" : "Group",
"display" : "QUARTET LDQT"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "NOT COMPLETED at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 3
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-milestone-3-Overall-Study-group-FG001",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-milestone-3-Overall-Study-group-FG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG001",
"type" : "Group",
"display" : "Candesartan"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "NOT COMPLETED at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"quantity" : {
"value" : 6
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-reason-Overall-Study-group-FG000",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-reason-Overall-Study-group-FG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG000",
"type" : "Group",
"display" : "QUARTET LDQT"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "Reasons for withdraw at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"category" : {
"text" : "Lost to Follow-up"
},
"quantity" : {
"value" : 3
}
}
]
},
{
"resourceType" : "Evidence",
"id" : "NCT03640312-flow-reason-Overall-Study-group-FG001",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
"identifier" : [
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-flow-reason-Overall-Study-group-FG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowEvidence",
"display" : "ParticipantFlowEvidence"
}
]
}
}
],
"variableDefinition" : [
{
"variableRole" : "population",
"observed" : {
"reference" : "#FG001",
"type" : "Group",
"display" : "Candesartan"
}
},
{
"variableRole" : "outcome",
"observed" : {
"display" : "Reasons for withdraw at Overall Study"
}
}
],
"statistic" : [
{
"statisticType" : {
"coding" : [
{
"system" : "https://fevir.net/sevco",
"code" : "STATO:0000047",
"display" : "Count"
}
]
},
"category" : {
"text" : "Lost to Follow-up"
},
"quantity" : {
"value" : 6
}
}
]
}
],
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-description",
"valueMarkdown" : "Example for EBMonFHIR IG"
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Composition/370512",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "370512",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03640312-participant-flow-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ParticipantFlowReport",
"display" : "ParticipantFlowReport"
}
],
"text" : "Participant Flow Report"
},
"date" : "2025-07-14T11:06:46.807Z",
"author" : [
{
"display" : "Joanne Dehnbostel"
}
],
"title" : "Participant Flow Report for QUARTET USA Trial",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "cite-as",
"targetMarkdown" : "Participant Flow Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370512. Revised 2025-07-14. Available at: https://fevir.net/resources/Composition/370512. Computable resource at: https://fevir.net/FLI/DocumentForComposition370512."
},
{
"type" : "derived-from",
"targetReference" : {
🔗 "reference" : "Composition/370502",
"type" : "Composition",
"display" : "Participant Flow Report for NCT03640312"
}
}
],
"section" : [
{
"title" : "Excluded",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
"type" : "EvidenceVariable",
"display" : "Excluded"
},
"entry" : [
{
"reference" : "#ExcludedCount",
"type" : "Evidence",
"display" : "Excluded from QUARTET USA Trial"
}
]
},
{
"title" : "Reasons for exclusion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/372461",
"type" : "EvidenceVariable",
"display" : "Reasons for exclusion from QUARTET USA Trial"
},
"entry" : [
{
"reference" : "#ReasonsForExclusion",
"type" : "Evidence",
"display" : "Reasons for exclusion from QUARTET USA Trial"
}
]
},
{
"title" : "Flow PreAssignment Details",
"code" : {
"text" : "FlowPreAssignmentDetails"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">NA - all enrolled participants were randomized.</div>"
}
},
{
"title" : "Flow Recruitment Details",
"code" : {
"text" : "FlowRecruitmentDetails"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">120 were consented and assessed for eligibility. 58 were excluded for not meeting either inclusion or exclusion criteria, declining participation, or not showing up for randomization visits. Thus, these 58 individuals were not randomized, and 62 participants were randomized</div>"
}
},
{
"title" : "Flow Group List",
"code" : {
"text" : "FlowGroupList"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">QUARTET LDQT, Candesartan</div>"
},
"entry" : [
{
"reference" : "#ScreenedGroup",
"type" : "Group",
"display" : "Screened for Participation"
},
{
"reference" : "#FG000",
"type" : "Group",
"display" : "QUARTET LDQT"
},
{
"reference" : "#FG001",
"type" : "Group",
"display" : "Candesartan"
}
]
},
{
"title" : "STARTED at Overall Study",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
],
"text" : "Participant Flow Results"
},
"focus" : {
"display" : "STARTED at Overall Study"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry" : [
{
"reference" : "#NCT03640312-flow-milestone-0-Overall-Study-group-FG000",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study"
},
{
"reference" : "#NCT03640312-flow-milestone-0-Overall-Study-group-FG001",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study"
}
]
},
{
"title" : "6 Week Follow Up at Overall Study",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
],
"text" : "Participant Flow Results"
},
"focus" : {
"display" : "6 Week Follow Up at Overall Study"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry" : [
{
"reference" : "#NCT03640312-flow-milestone-1-Overall-Study-group-FG000",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study"
},
{
"reference" : "#NCT03640312-flow-milestone-1-Overall-Study-group-FG001",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study"
}
]
},
{
"title" : "COMPLETED at Overall Study",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
],
"text" : "Participant Flow Results"
},
"focus" : {
"display" : "COMPLETED at Overall Study"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry" : [
{
"reference" : "#NCT03640312-flow-milestone-2-Overall-Study-group-FG000",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study"
},
{
"reference" : "#NCT03640312-flow-milestone-2-Overall-Study-group-FG001",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study"
}
]
},
{
"title" : "NOT COMPLETED at Overall Study",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
],
"text" : "Participant Flow Results"
},
"focus" : {
"display" : "NOT COMPLETED at Overall Study"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry" : [
{
"reference" : "#NCT03640312-flow-milestone-3-Overall-Study-group-FG000",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study"
},
{
"reference" : "#NCT03640312-flow-milestone-3-Overall-Study-group-FG001",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study"
}
]
},
{
"title" : "Reasons for withdraw at Overall Study",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
],
"text" : "Participant Flow Results"
},
"focus" : {
"display" : "Reasons for withdraw at Overall Study"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry" : [
{
"reference" : "#NCT03640312-flow-reason-Overall-Study-group-FG000",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study"
},
{
"reference" : "#NCT03640312-flow-reason-Overall-Study-group-FG001",
"type" : "Evidence",
"display" : "ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study"
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot3. Generated 2025-09-04
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change